FDA Publishes Psychedelic Drug Development Guidance, Sets Hearing Date

FDA Issues First Comprehensive Psychedelic Development Framework

The 47-page draft guidance, titled "Psychedelic Drugs: Considerations for Clinical Investigations," establishes FDA's regulatory expectations for Phase 2 and Phase 3 trials of Schedule I psychedelics under the Investigational New Drug (IND) pathway. It addresses patient selection, dosing protocols, therapist training requirements, and adverse-event monitoring for substances including psilocybin, psilocin, MDMA, LSD, DMT, and mescaline.

The guidance doesn't create new regulatory authority. On a strict reading, it codifies existing FDA positions scattered across individual IND correspondence and advisory-committee transcripts since 2018. The agency opened a 60-day public comment period closing September 12, 2026.

FDA's Center for Drug Evaluation and Research (CDER) issued the guidance under delegated authority from Commissioner Dr. Robert Califf, according to the Federal Register notice published concurrently.

Key Clinical Trial Requirements and Manufacturing Standards

The guidance mandates independent Data Safety Monitoring Boards (DSMBs) for all Phase 2 trials enrolling more than 50 participants and requires real-time adverse-event reporting within 24 hours for serious psychological reactions. Sponsors must submit detailed therapist-training curricula. They must also demonstrate inter-rater reliability scores above 0.80 for blinding assessments.

Manufacturing standards mirror those in FDA's 2018 botanical-drug guidance. Sponsors must:

• Establish certificate-of-analysis protocols for each production batch
• Validate purity thresholds of ≥95% for synthetic compounds
• Document chain-of-custody under DEA Schedule I security requirements
• Submit stability data for storage conditions and shelf-life claims

Cannabis-derived psychedelics aren't addressed. FDA explicitly excludes THC, CBD, and delta-8-THC from the scope, stating those compounds fall under separate botanical-drug and cannabis-derived-drug pathways.

Senate Hearing Targets FDA Approval Timeline and Access Pathways

The Senate HELP Committee scheduled a July 23, 2026 hearing titled "Psychedelic Therapies: FDA's Role in Ensuring Safe and Equitable Access," with Dr. Califf and CDER Director Dr. Patrizia Cavazzoni confirmed as witnesses. Committee Chair Sen. Bernie Sanders (I-VT) and Ranking Member Sen. Bill Cassidy (R-LA) issued a joint statement calling for "transparent timelines" on pending New Drug Applications (NDAs) for MDMA-assisted therapy and psilocybin for treatment-resistant depression.

Two NDAs are under FDA review as of July 14, 2026. Lykos Therapeutics submitted an NDA for MDMA-assisted therapy for PTSD in December 2023, with a PDUFA goal date of August 11, 2024, later extended to Q3 2026. Compass Pathways submitted an NDA for COMP360 psilocybin therapy in March 2025, with a PDUFA date of January 2027.

The hearing notice doesn't reference cannabis rescheduling or the DEA's pending marijuana rule, which remains under OMB review since April 2024. For full background on federal cannabis scheduling proceedings, see the CannIntel topic hub on FDA psychedelic guidance.

State-Level Psilocybin Programs Face Federal Compliance Gap

Oregon and Colorado operate state-licensed psilocybin service programs under state law, but the new FDA guidance doesn't create a compliance pathway for those programs because psilocybin remains Schedule I under the Controlled Substances Act. Oregon's Psilocybin Services Section licensed 22 service centers and 89 facilitators as of June 2026, according to the Oregon Health Authority. Colorado's Natural Medicine Division began accepting applications in May 2025.

State-licensed administration of Schedule I substances "doesn't satisfy FDA requirements for lawful marketing," the guidance states, and such programs operate "outside the federal drug-approval framework." FDA hasn't issued warning letters to state-licensed psilocybin providers, nor has DEA announced enforcement priorities targeting those programs.

Liability and insurance hinge on this distinction. State-licensed facilitators can't obtain federal malpractice coverage or product-liability insurance for Schedule I administration, and patients in state programs can't access therapies through Medicare, Medicaid, or private insurers bound by federal formularies.

Industry Reaction and Next Regulatory Milestones

Psychedelic industry trade groups welcomed the guidance as a step toward regulatory clarity but criticized the exclusion of Right to Try and Expanded Access pathways for terminally ill patients. The Multidisciplinary Association for Psychedelic Studies (MAPS) issued a statement calling for FDA to establish a pre-approval Expanded Access program for MDMA therapy, citing 15,000 patient requests received since 2021.

State medical-cannabis programs aren't addressed, nor is the interaction between psychedelic therapies and cannabis use. Sponsors must document participants' cannabis use in trial protocols, but FDA doesn't mandate exclusion of cannabis users from psychedelic trials.

Three regulatory deadlines converge in Q3 2026:

• August 11, 2026: FDA decision on Lykos MDMA NDA (extended PDUFA date)
• September 12, 2026: Close of public comment period on draft guidance
• September 30, 2026: End of fiscal year for FDA user-fee commitments under PDUFA VII

Final guidance typically publishes 6-12 months after comment-period closure, suggesting a finalized framework by Q2 2027.